👨‍💼 CUSTOMER CARE NO +918468865271

⭐ TOP RATED SELLER ON AMAZON, FLIPKART, EBAY & WALMART

🏆 TRUSTED FOR 10+ YEARS

  • From India to the World — Discover Our Global Stores

🚚 Extra 10% + Free Shipping? Yes, Please!

Shop above ₹5000 and save 10% instantly—on us!

THANKYOU10

The Risks of Prescription Drugs (A Columbia / SSRC Book (Privatization of Risk))

Sale price Rs.1,360.00 Regular price Rs.1,700.00
Tax included


Genuine Products Guarantee

We guarantee 100% genuine products, and if proven otherwise, we will compensate you with 10 times the product's cost.

Delivery and Shipping

Products are generally ready for dispatch within 1 day and typically reach you in 3 to 5 days.

Get 100% refund on non-delivery or defects

On Prepaid Orders

Author: Light, Donald

Brand: Columbia University Press

Binding: paperback

Number Of Pages: 184

Release Date: 14-10-2010

Details: Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and m

EAN: 9780231146937

Package Dimensions: 8.0 x 5.4 x 0.6 inches

Languages: English